<--- Back to Details
First PageDocument Content
Immunology / RTT / Prodrugs / Antineoplastic drugs / Hematopoietic stem cell transplantation / Surgical oncology / Cyclophosphamide / Chemotherapy / Autoimmune disease / Autoimmunity / Systemic lupus erythematosus / Disease-modifying antirheumatic drug
Date: 2007-02-23 01:13:16
Immunology
RTT
Prodrugs
Antineoplastic drugs
Hematopoietic stem cell transplantation
Surgical oncology
Cyclophosphamide
Chemotherapy
Autoimmune disease
Autoimmunity
Systemic lupus erythematosus
Disease-modifying antirheumatic drug

Bone Marrow Transplantation, 869–879 & 2005 Nature Publishing Group All rights reserved $30.00 www.nature.com/bmt Autografting

Add to Reading List

Source URL: www.nature.com

Download Document from Source Website

File Size: 202,46 KB

Share Document on Facebook

Similar Documents

Edorium J Disabil Rehabil 2015;1:9–11. www.edoriumjournals.com/ej/dr Letter to Editors	  Massoni et al. 

Edorium J Disabil Rehabil 2015;1:9–11. www.edoriumjournals.com/ej/dr Letter to Editors Massoni et al. 

DocID: 1ru4d - View Document

Original Research  Maternal and Neonatal Outcomes of Dose-Dense Chemotherapy for Breast Cancer in Pregnancy Elyce Cardonick,

Original Research Maternal and Neonatal Outcomes of Dose-Dense Chemotherapy for Breast Cancer in Pregnancy Elyce Cardonick,

DocID: 1rr4j - View Document

EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i

EISAI AND PIQUR SIGN LANDMARK COLLABORATION AGREEMENT TO INVESTIGATE HALAVEN® (ERIBULIN) AND PQR309 IN HARD TO TREAT FORM OF BREAST CANCER Agreement will see eribulin used in combination with novel PI3K/mTOR inhibitor i

DocID: 1rhhk - View Document

When Patients Win, We All Win™  Provectus Biopharmaceuticals, Inc Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigation

When Patients Win, We All Win™ Provectus Biopharmaceuticals, Inc Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigation

DocID: 1rgN5 - View Document

Intralesional therapy is a possible treatment option for patients with metastatic melanoma due to its good local response and tolerable adverse-event profile.  Photo courtesy of Dina Potter. Sunny Tree. 48

Intralesional therapy is a possible treatment option for patients with metastatic melanoma due to its good local response and tolerable adverse-event profile. Photo courtesy of Dina Potter. Sunny Tree. 48" × 60".

DocID: 1rePY - View Document